IL2 and Miyoshi myopathy: Wilhelm and coworkers first demonstrated that in vivo Vγ9Vδ2 T cell stimulation by Pam and low-dose IL-2 was safe and could induce objective tumor responses in patients with low-grade non-Hodgkin lymphoma (NHL, n = 11) and multiple myeloma (MM, n = 8) [11].